Login to Your Account



Maxim's Preclinical Cancer Work Nets Potential $27M Myriad Deal

By Randall Osborne


Wednesday, December 3, 2003
Maxim Pharmaceuticals Inc. nailed down a potential $27 million licensing deal centered on its apoptosis-inducing cancer compounds with Myriad Genetics Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription